Rhythm Pharmaceuticals (RYTM)
(Real Time Quote from BATS)
$52.08 USD
-0.72 (-1.36%)
Updated Sep 23, 2024 02:56 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Cash flow Statements
Fiscal Year End for Rhythm Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -184.68 | -181.12 | -69.61 | -134.00 | -140.73 |
Depreciation/Amortization & Depletion | 15.12 | 7.06 | 1.16 | 0.69 | 0.83 |
Net Change from Assets/Liabilities | 4.81 | -19.72 | 1.90 | -6.13 | 5.07 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 28.60 | 20.35 | -79.45 | 17.46 | 12.08 |
Net Cash From Operating Activities | -136.16 | -173.43 | -146.00 | -121.98 | -122.75 |
Property & Equipment | -5.71 | -0.28 | -0.43 | -0.21 | -3.39 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.05 | 32.31 | -163.73 | 158.75 | -24.59 |
Other Investing Activities | 0.00 | -4.00 | 102.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -5.67 | 28.03 | -62.16 | 158.53 | -27.97 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 57.40 | 141.49 | 166.48 | 2.01 | 163.47 |
Issuance (Repayment) of Debt | 16.97 | 72.34 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 74.37 | 213.83 | 166.48 | 2.01 | 163.47 |
Effect of Exchange Rate Changes | -0.14 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -67.60 | 68.43 | -41.68 | 38.56 | 12.75 |
Cash at Beginning of Period | 128.01 | 59.58 | 101.26 | 62.70 | 49.94 |
Cash at End of Period | 60.41 | 128.01 | 59.58 | 101.26 | 62.70 |
Diluted Net EPS | -3.20 | -3.47 | -1.40 | -3.04 | -3.86 |
Fiscal Year End for Rhythm Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -173.63 | -141.37 | -184.68 | -143.05 | -98.88 |
Depreciation/Amortization & Depletion | 0.80 | 4.41 | 15.12 | 10.68 | 0.90 |
Net Change from Assets/Liabilities | -4.33 | -2.19 | 4.81 | -4.10 | -6.93 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 107.35 | 98.40 | 28.60 | 29.69 | 27.39 |
Net Cash From Operating Activities | -69.82 | -40.74 | -136.16 | -106.77 | -77.52 |
Property & Equipment | -40.00 | -40.00 | -5.71 | -5.72 | -5.44 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 61.49 | 70.05 | 0.05 | -22.59 | 72.10 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 21.49 | 30.05 | -5.67 | -28.31 | 66.66 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 147.28 | 7.03 | 57.40 | 52.40 | 1.56 |
Issuance (Repayment) of Debt | -5.76 | -2.78 | 16.97 | 19.55 | -2.66 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 8.90 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 150.42 | 4.24 | 74.37 | 71.95 | -1.10 |
Effect of Exchange Rate Changes | -0.37 | -0.07 | -0.14 | 0.05 | -0.03 |
Net Change In Cash & Equivalents | 101.72 | -6.52 | -67.60 | -63.08 | -11.99 |
Cash at Beginning of Period | 60.41 | 60.41 | 128.01 | 128.01 | 128.01 |
Cash at End of Period | 162.13 | 53.89 | 60.41 | 64.92 | 116.01 |
Diluted Net EPS | -0.55 | -2.35 | -0.70 | -0.76 | -0.82 |